646 studies found for:    trastuzumab
Show Display Options
Rank Status Study
21 Recruiting A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Condition: Neoplasms, Breast
Interventions: Drug: lapatinib;   Drug: trastuzumab;   Drug: Aromatase inhibitor
22 Terminated Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Cardiac Toxicity;   Inflammatory Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: paclitaxel;   Biological: trastuzumab;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Drug: tamoxifen citrate;   Other: laboratory biomarker analysis
23 Terminated Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
Condition: Metastatic Breast Cancer
Interventions: Drug: G-CSF;   Drug: trastuzumab;   Drug: vinorelbine;   Drug: saline
24 Active, not recruiting Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
Condition: Advanced Cancers
Interventions: Drug: Pazopanib;   Drug: Lapatinib;   Drug: Trastuzumab (Herceptin®)
25 Active, not recruiting A Study to Compare Subcutaneous Versus Intravenous Administration of Herceptin (Trastuzumab) in Women With HER2-Positive Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin];   Drug: docetaxel;   Drug: 5-fluorouracil;   Drug: epirubicin;   Drug: cyclophosphamide
26 Active, not recruiting A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.
Condition: Breast Cancer
Interventions: Drug: Docetaxel, Carboplatin and Trastuzumab;   Drug: Docetaxel, Carboplatin, Trastuzumab and Lapatinib
27 Completed PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Radiation: PET Imaging With Cu-64 Labeled Trastuzumab
28 Active, not recruiting Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Condition: Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Bevacizumab;   Drug: Docetaxel
29 Recruiting A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
Condition: Breast Cancer
Interventions: Drug: T-DM1;   Drug: Trastuzumab
30 Completed
Has Results
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Trastuzumab emtansine [Kadcyla]
31 Recruiting NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
Condition: HER2-positive, Newly Diagnosed, Primary Breast Cancer, Neoadjuvant Therapy, Trastuzumab
Interventions: Drug: BKM120;   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: Placebo
32 Unknown  Trastuzumab Optimization Trial in Breast Cancer
Condition: Metastatic or Locally Advanced Breast Cancer
Intervention: Drug: trastuzumab
33 Completed A Study of Administration of Trastuzumab (Herceptin) by a Single-use Injection Device Versus a Handheld Syringe
Condition: Healthy Volunteer
Intervention: Drug: trastuzumab [Herceptin]
34 Completed Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
Condition: Carcinoma, Metastatic Breast
Interventions: Drug: CPG 7909;   Drug: Herceptin®
35 Recruiting Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis
Conditions: Metastatic Breast Cancer;   Carcinomatous Meningitis
Intervention: Drug: Trastuzumab
36 Completed
Has Results
Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Herceptin;   Drug: Navelbine;   Drug: Taxotere;   Drug: Carboplatin
37 Active, not recruiting BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Trastuzumab;   Drug: Carboplatin;   Drug: Bevacizumab;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
38 Active, not recruiting Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Everolimus;   Drug: Trastuzumab
39 Recruiting Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer
Conditions: Brain Metastases From HER2 and Breast Cancer;   Advanced HER2-positive Breast Cancer
Interventions: Drug: ARRY-380 Twice Daily Dosage;   Drug: ARRY-380 Once Daily;   Drug: Trastuzumab
40 Active, not recruiting Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
Condition: Advanced HER2-positive Breast Cancer
Interventions: Drug: AUY922;   Drug: Trastuzumab

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years